NORGES BANK Initiates New Position in Gilead Sciences, Inc. (GILD)
NORGES BANK, a registered investment adviser, initiated a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during Q2 2026, according to its most recent 13F filing with the…
Gilead Sciences, Inc. (NASDAQ:GILD) · new position
Institution
NORGES BANK
Institution type
investment_adviser
Reporting period
Q2 2026
Shares
21,965,555
Position value
$2.8B
Position change
100%
At a glance
Key takeaways
01NORGES BANK established a new position in Gilead Sciences (GILD) during Q2 2026, purchasing approximately 21.97 million shares valued at $2.8 billion.
02Gilead Sciences trades at $135.68 per share with a market capitalization of $152.9 billion, and this $2.78 billion position represents a significant institutional holding.
0313F filings reflect portfolio holdings as of quarter-end and are filed up to 45 days later, so the actual position may have changed since the filing date.
04Healthcare sector stocks have attracted institutional attention due to long-term demand from an aging population, though regulatory developments and pipeline progress can significantly impact institutional positioning in this sector.
Filing Details
NORGES BANK, a registered investment adviser, initiated a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during Q2 2026, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor purchased 21,965,555 shares of the Healthcare company, valued at approximately $2.8B as of the filing date.
Market Context
Gilead Sciences, Inc.'s stock currently trades at $135.68 with a market capitalization of $152.9B.
A new institutional position can signal growing confidence in a company's prospects. When large asset managers like NORGES BANK establish stakes, it often reflects months of due diligence and a conviction that the stock is undervalued or poised for growth. Retail investors often track 13F filings to identify stocks that institutional money is moving into.
Healthcare stocks have attracted institutional attention as an aging population drives long-term demand. Gilead Sciences, Inc. operates in a sector where regulatory developments and pipeline progress can significantly impact institutional positioning.
The size of this position — $2.78 billion — places it among the more significant institutional holdings in Gilead Sciences, Inc. Large positions like this can influence trading dynamics and are closely watched by market participants tracking smart money flows.
Investors should note that 13F filings reflect holdings as of the end of the reporting quarter and are filed up to 45 days later. The position may have changed since the filing date. 13F data is most useful when analyzed alongside other signals such as insider transactions, analyst ratings, and fundamental trends.
A 13F filing is a quarterly SEC report required for institutional managers with over $100 million in assets. It discloses equity holdings, providing transparency into how firms like NORGES BANK position their portfolios.